TroVax® + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
47
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Ovarian Cancer
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Trial Timeline
Nov 1, 2013 → Apr 19, 2019
NCT ID
NCT01556841About TroVax® + Placebo
TroVax® + Placebo is a phase 2 stage product being developed by Oxford Biomedica for Ovarian Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT01556841. Target conditions include Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer.
Hype Score Breakdown
Clinical
17
Activity
12
Company
5
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01556841 | Phase 2 | Completed |
Competing Products
20 competing products in Ovarian Cancer